PDF(Pubmed)
Abstract：
UNASSIGNED: Non-small cell lung cancer (NSCLC) with TP53 mutations has a worse prognosis. It was generally more resistant to chemotherapy and radiation. Our aim was to investigate the correlation between the TP53 co-mutated gene and clinical features, and prognostic value in patients with NSCLC.
UNASSIGNED: Seventy-three patients with a diagnosis of NSCLC at our hospital were recruited. They were divided into the TP53 mutation status (minor) (TP53 MU) and TP53 wild-type (major) (TP53 WT) groups according to their clinical characteristics after their mutation data and clinical information were collected. Serum markers were compared between groups using Mann-Whitney U test. Other clinical factors were compared between groups using χ2 test and Fisher exact test. The log-rank test was used to compare survival curves.
UNASSIGNED: Of the 73 patients with NSCLC, 37 (50.68%) were found to carry TP53 mutation. TP53 MU and TP53 WT groups (n = 36) showed a significant difference in the number of smokers, incidence of squamous cell carcinoma, EGFR mutation, and number of advanced patients (P < .05), while gender, age, lymph node metastasis, and KRAS mutation did not differ significantly between the 2 groups. The survival curves in the TP53/KRAS and the TP53/EGFR co-mutation groups suggest that patients with NSCLC may have a shorter progression-free survival (PFS) if they carry one of the 2 types of co-mutation.
UNASSIGNED: TP53 gene mutations are more common in patients with NSCLC and squamous cell carcinoma. New predictive markers for NSCLC prognosis may be TP53/KRAS and TP53/EGFR co-mutations.
UNASSIGNED: Seventy-three patients with a diagnosis of NSCLC at our hospital were recruited. They were divided into the TP53 mutation status (minor) (TP53 MU) and TP53 wild-type (major) (TP53 WT) groups according to their clinical characteristics after their mutation data and clinical information were collected. Serum markers were compared between groups using Mann-Whitney U test. Other clinical factors were compared between groups using χ2 test and Fisher exact test. The log-rank test was used to compare survival curves.
UNASSIGNED: Of the 73 patients with NSCLC, 37 (50.68%) were found to carry TP53 mutation. TP53 MU and TP53 WT groups (n = 36) showed a significant difference in the number of smokers, incidence of squamous cell carcinoma, EGFR mutation, and number of advanced patients (P < .05), while gender, age, lymph node metastasis, and KRAS mutation did not differ significantly between the 2 groups. The survival curves in the TP53/KRAS and the TP53/EGFR co-mutation groups suggest that patients with NSCLC may have a shorter progression-free survival (PFS) if they carry one of the 2 types of co-mutation.
UNASSIGNED: TP53 gene mutations are more common in patients with NSCLC and squamous cell carcinoma. New predictive markers for NSCLC prognosis may be TP53/KRAS and TP53/EGFR co-mutations.
摘要：
■TP53突变的非小细胞肺癌（NSCLC）预后较差。它通常对化疗和放疗更有抵抗力。我们的目的是研究TP53共突变基因与临床特征之间的相关性。非小细胞肺癌患者的预后价值。
■招募了在我们医院诊断为非小细胞肺癌的73例患者。在收集其突变数据和临床信息后，根据其临床特征将其分为TP53突变状态（次要）（TP53MU）和TP53野生型（主要）（TP53WT）组。使用Mann-WhitneyU检验比较各组之间的血清标志物。使用χ2检验和Fisher精确检验比较各组之间的其他临床因素。使用对数秩检验比较存活曲线。
■在73例非小细胞肺癌患者中，发现37例(50.68%)携带TP53突变。TP53MU和TP53WT组(n=36)在吸烟者人数上有显著差异,鳞状细胞癌的发病率，EGFR突变,和晚期患者人数（P<0.05），而性别,年龄,淋巴结转移,而KRAS突变在两组间无显著差异.TP53/KRAS和TP53/EGFR共突变组的生存曲线表明，如果NSCLC患者携带2种类型的共突变之一，则他们的无进展生存期（PFS）可能较短。
■TP53基因突变在NSCLC和鳞状细胞癌患者中更为常见。NSCLC预后的新预测标志物可能是TP53/KRAS和TP53/EGFR共突变。
■招募了在我们医院诊断为非小细胞肺癌的73例患者。在收集其突变数据和临床信息后，根据其临床特征将其分为TP53突变状态（次要）（TP53MU）和TP53野生型（主要）（TP53WT）组。使用Mann-WhitneyU检验比较各组之间的血清标志物。使用χ2检验和Fisher精确检验比较各组之间的其他临床因素。使用对数秩检验比较存活曲线。
■在73例非小细胞肺癌患者中，发现37例(50.68%)携带TP53突变。TP53MU和TP53WT组(n=36)在吸烟者人数上有显著差异,鳞状细胞癌的发病率，EGFR突变,和晚期患者人数（P<0.05），而性别,年龄,淋巴结转移,而KRAS突变在两组间无显著差异.TP53/KRAS和TP53/EGFR共突变组的生存曲线表明，如果NSCLC患者携带2种类型的共突变之一，则他们的无进展生存期（PFS）可能较短。
■TP53基因突变在NSCLC和鳞状细胞癌患者中更为常见。NSCLC预后的新预测标志物可能是TP53/KRAS和TP53/EGFR共突变。
